EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization

Zrinka Duvnjak iD, Robin Michelet iD, Casper Steenholdt iD, Ella S K Widigson iD, Cæcilie Skejø iD, João A Abrantes iD, Wilhelm Huisinga iD, Mette Julsgaard iD, Charlotte Kloft iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70145 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, 2026. Written by Zrinka Duvnjak and 8 co-authors. Institution: Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Models, Biological, Inflammatory Bowel Diseases, Gastrointestinal Agents. Cited 1 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: A.P. Moeller Foundation of the Advancement of Medical Science, Takeda Pharma A/S, NOVO Nordisk Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy remains poorly characterized, despite active inflammatory bowel diseases (IBD) being the greatest risk factor for adverse pregnancy outcomes. To quantify pregnancy‐induced changes, vedolizumab concentrations from 39 pregnant patients on various dosing regimens were analyzed using a sequential albumin‐trend/PK modeling approach, extending a published vedolizumab non‐pregnancy model. Albumin trends were first characterized using a polynomial mixed‐effect model. Then, individual changes in albumin from their pre‐pregnancy concentrations, implemented as time‐varying patient‐influential factor (covariate) in the PK model, served as potential biomarker of pregnancy‐induced plasma volume expansion. The modeling framework allowed model‐informed imputation of missing covariate data, extraction of hemodilution effect, and estimation of pre‐pregnancy PK parameters. Due to albumin change, the central volume of distribution increased 52.4%, consistent with known gestational plasma volume expansion, while clearance increased to 38.6%. An additional third‐trimester effect of gestational age, potentially reflecting transplacental transfer, increased clearance by an additional 33.3 percentage points. These changes led to a 49.5% decline in vedolizumab trough concentrations ( C min ) by late pregnancy. To maintain efficacious pre‐pregnancy exposure (dependent on the individual dosing interval), dosing intervals were gradually shortened for approximately one‐third (e.g., to up to 5.6 weeks for pre‐pregnancy 8‐week regimens). Optimized dosing times were summarized in an easy‐to‐use nomogram‐like plot. This work provides the first population PK model of vedolizumab in pregnancy. By integrating physiologically motivated pregnancy effects, it advanced quantitative understanding of mAbs PK in pregnancy with potential application to other biologics and provides optimized dosing strategies to mitigate risks of adverse pregnancy outcomes.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedModels, BiologicalInflammatory Bowel DiseasesGastrointestinal AgentsPregnancy ComplicationsSerum AlbuminSerum Albumin, HumanHumansFemalePregnancyAdultYoung AdultGestational AgeDose-Response Relationship, Drug

Substances

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsSerum AlbuminSerum Albumin, Human

Authors and institutions

  • Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
  • Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany.
  • Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
  • Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.

ORCID profiles: Zrinka Duvnjak, Robin Michelet, Casper Steenholdt, Ella S K Widigson, Cæcilie Skejø, João A Abrantes, Wilhelm Huisinga, Mette Julsgaard, Charlotte Kloft

Funding

  • A.P. Moeller Foundation of the Advancement of Medical Science
  • Takeda Pharma A/S
  • NOVO Nordisk Foundation
  • Novo Nordisk Fonden

Cite

APA

Duvnjak, Z., Michelet, R., Steenholdt, C., Widigson, E. S. K., Skejø, C., Abrantes, J. A., Huisinga, W., Julsgaard, M., & Kloft, C. (2026). Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70145

Vancouver

Duvnjak Z, Michelet R, Steenholdt C, Widigson ESK, Skejø C, Abrantes JA, et al. Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70145

BibTeX
@article{Duvnjak2026,
  author = {Duvnjak, Zrinka and Michelet, Robin and Steenholdt, Casper and Widigson, Ella S K and Skejø, Cæcilie and Abrantes, João A and Huisinga, Wilhelm and Julsgaard, Mette and Kloft, Charlotte},
  title = {Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70145}
}
Start for free →